Literature DB >> 11177396

Comparison of Vif sequences from diverse geographical isolates of HIV type 1 and SIV(cpz) identifies substitutions common to subtype C isolates and extensive variation in a proposed nuclear transport inhibition signal.

E B Stephens1, D K Singh, E Pacyniak, C McCormick.   

Abstract

We compared the Vif sequences from more than 100 group M and O strains of HIV-1 isolated from diverse geographical regions and various subtypes, in order to identify regions of high variability and those amino acid residues that were highly conserved or invariant. Our analysis found that there were 10 highly conserved domains with additional invariant residues located throughout the protein. Our analysis revealed that in the highly conserved amino-terminal domain, all subtype C isolates examined had a methionine-to-leucine substitution at position 8 and most subtype C isolates had an arginine-to-lysine substitution at position 17 of the protein. Our analysis revealed that the MAP kinase phosphorylation sites, and the cysteine residues at positions 114 and 133, were conserved in Vif sequences from group M, group O, and SIV cpz isolates. Our analysis also shows that the RKKR motif at positions 90--93, proposed as a nuclear transport inhibition signal (NTIS), was conserved neither in different geographical group M and O HIV-1 isolates nor in SIVcpz.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11177396     DOI: 10.1089/08892220150217256

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Characterisation of near-full length genome sequences of three South African human immunodeficiency virus type 1 subtype C isolates.

Authors:  Gillian M Hunt; Maria A Papathanasopoulos; Glenda E Gray; Caroline T Tiemessen
Journal:  Virus Genes       Date:  2003-01       Impact factor: 2.332

2.  The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.

Authors:  Mawuena Binka; Marcel Ooms; Myeika Steward; Viviana Simon
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Differential anti-APOBEC3G activity of HIV-1 Vif proteins derived from different subtypes.

Authors:  Yukie Iwabu; Masanobu Kinomoto; Masashi Tatsumi; Hideaki Fujita; Mari Shimura; Yoshitaka Tanaka; Yukihito Ishizaka; David Nolan; Simon Mallal; Tetsutaro Sata; Kenzo Tokunaga
Journal:  J Biol Chem       Date:  2010-09-10       Impact factor: 5.157

4.  Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Authors:  Agatha Masemola; Tumelo Mashishi; Greg Khoury; Phineas Mohube; Pauline Mokgotho; Efthyia Vardas; Mark Colvin; Lynn Zijenah; David Katzenstein; Rosemary Musonda; Susan Allen; Newton Kumwenda; Taha Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive M Gray
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  The role of MHC class I allele Mamu-A*07 during SIV(mac)239 infection.

Authors:  Jason S Reed; John Sidney; Shari M Piaskowski; Chrystal E Glidden; Enrique J León; Benjamin J Burwitz; Holly L Kolar; Christopher M Eernisse; Jessica R Furlott; Nicholas J Maness; Andrew D Walsh; Richard A Rudersdorf; Wilfried Bardet; Curtis P McMurtrey; David H O'Connor; William H Hildebrand; Alessandro Sette; David I Watkins; Nancy A Wilson
Journal:  Immunogenetics       Date:  2011-07-06       Impact factor: 3.330

6.  The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its Zinc-binding domain.

Authors:  Sandrina Dafonseca; Pascale Coric; Bernard Gay; Saw See Hong; Serge Bouaziz; Pierre Boulanger
Journal:  Virol J       Date:  2008-12-23       Impact factor: 4.099

Review 7.  Running loose or getting lost: how HIV-1 counters and capitalizes on APOBEC3-induced mutagenesis through its Vif protein.

Authors:  Carsten Münk; Björn-Erik O Jensen; Jörg Zielonka; Dieter Häussinger; Christel Kamp
Journal:  Viruses       Date:  2012-11-14       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.